anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Weight stigma is defined as negative misconception and stereotypes associated with weight, and it is commonly experienced during pregnancy. Weight stigma during pregnancy may be sourced from trusted close relationships including family members, partners, and friends. Social support is a necessary psychosocial factor for optimal health and wellbeing throughout pregnancy, and weight stigma sourced from these integral relationships may negatively affect health outcomes. The purpose of this study was to assess the impact of weight stigma from close others on maternal health outcomes.
METHODS: A survey was administered via Qualtrics to pregnant women (≥ 13 weeks, residence within the United States or Canada, ≥ 18 years old, singleton pregnancy). During pregnancy, participants completed questionnaires identifying whether they had experienced weight stigma from a close relationship (i.e., family, partners, or friends), how often, and relationship quality scales for each source. At three months postpartum, they were surveyed about their pregnancy outcomes including gestational diabetes, gestational hypertension, preeclampsia, chronic pain, anxiety/depression. They also completed the Edinburgh Postpartum Depression Scale (EPDS), and a linear regression was performed with frequency of weight stigma. Logistic regressions were performed between frequency of weight stigma and health outcomes. If significant, relationship quality was tested as a potential mediator. Significance was accepted as p < 0.05.
RESULTS: 463 participants completed both surveys of which 86% had experienced weight stigma from close others. Frequency of weight stigma was significantly associated with chronic pain (β = 0.689, p < 0.001), and anxiety/depression (β = 0.404, p = 0.005). The relationship between frequency of weight stigma in pregnancy and chronic pain was mediated by quality of all relationships. Family relationship quality mediated between frequency of weights stigma and anxiety/depression. Frequency of weight stigma was significantly associated with depression symptom severity measured by the EPDS (β = 0.634, p < 0.001).
CONCLUSION: These findings underscore the issue of weight stigma and show that experiencing this from trusted close others is associated with poor health outcomes like chronic pain. Advocacy efforts to mitigate weight stigma in pregnancy and strengthen close relationships to improve maternal health and wellbeing is warranted.
Recombinant human GM-CSF (Sargramostim) was administered at 100mcg/day on days 1-4 following each vaccine. Given subcutaneously (s.c.) at site of vaccine.
OBJECTIVE: To examine the association between cerebral artery stenosis and depressive symptoms in elderly patients.
METHODS: The study participants were 365 patients aged ≥65 years who visited the psychiatric outpatient clinic, Samsung Medical Center between January 1, 2000, and December 31, 2019, and were diagnosed with depressive disorder. They had brain imaging tests including magnetic resonance angiography (MRA), psychological evaluations including the 15-item Geriatric Depression Scale (GDS-15), and lab tests. Individuals' cerebral artery stenosis was identified and the association with significant depressive symptoms was examined.
RESULTS: Of the 365 subjects, 108 had at least one location of cerebral artery stenosis (29.6 %). The mean score of GDS-15 in the stenosis group was 8.1 (SD, 3.8), higher than the mean GDS-15 score of 6.5 (SD, 4.0) for the group without stenosis (p < 0.001). Compared to no middle cerebral artery (MCA) stenosis, having MCA stenosis was associated with significant depressive symptoms (p = 0.005). Compared to no posterior cerebral artery (PCA) stenosis, having left PCA stenosis was associated with significant depressive symptoms (p = 0.022). In the multivariable linear regression analysis, only bilateral MCA stenosis had a positive association with the score of GDS-15 (p = 0.013).
CONCLUSION: Bilateral MCA stenosis and left PCA stenosis are associated with significant depressive symptoms among elderly patients, with bilateral MCA stenosis positively associated with the severity of depression.
The present invention discloses anti-mycobacterium tuberculosis monoclonal antibody, an epitope recognized by the anti-mycobacterium tuberculosis monoclonal antibody, and a use thereof. The present invention provides a hybridoma cell line with the function of stable secretion of anti-mycobacterium tuberculosis CsdA monoclonal antibody. The microorganism preservation number of the hybridoma cell line is CGMCCNo.5077. The present invention further provides the monoclonal antibody secreted by the hybridoma cell line. The monoclonal antibody provides response specificity for the mycobacterium tuberculosis CsdA, and is the specific antibody against the mycobacterium tuberculosis CsdA. The present invention further provides an epitope peptide, wherein the epitope peptide can be specially combined with the monoclonal antibody. With the epitope peptide, a foundation is provided for further determination of the action mechanism of the CsdA in the mycobacterium tuberculosis, a new idea is provided for inhibition of the mycobacterium tuberculosis growth, such that the target drugs of the specific somatic antigen are easily found so as to realize prevention and treatment of tuberculosis.
Patients are treated with glucocorticoids and mycophenolate mofetil in remission induction period (6 months), during which glucocorticoids are tapered regularly and discontinued in 6 months. Afterwards, patients are treated with low dose mycophenolate (1-1.5g/day) during remission maintenance period for 12 months.
BACKGROUND: Uni- or bilateral peripheralvestibular impairment causes objective spatial orientation deficits, which can be measured using pen-and-paper-tests or sensorimotor tasks (navigation or pointing). For patients' subjective orientation abilities, questionnaires are commonly used (e.g., Santa Barbara sense of direction scale [SBSODS]). However, the relationship between subjective assessment of spatial skills and objective vestibular function has only been scarcely investigated.
METHODS: A total of 177 patients (mean age 57.86 ± 17.53 years, 90 females) who presented in our tertiary Center for Vertigo and Balance Disorders underwent neuro-otological examinations, including bithermal water calorics, video head impulse test (vHIT), and testing of the subjective visual vertical (SVV), and filled out the SBSODS (German version). Correlation analyses and linear multiple regression model analyses were performed between vestibular test results and self-assessment scores. Additionally, groupwise vestibular function for patients with low, average, and high self-report scores was analyzed.
RESULTS: Forty-two patients fulfilled the diagnostic criteria for bilateral vestibulopathy, 93 for chronic unilateral vestibulopathy (68 unilateral caloric hypofunction and 25 isolated horizontal vestibulo-ocular reflex deficits), and 42 patients had normal vestibular test results. SBSODS scores showed clear sex differences with higher subjective skill levels in males (mean score males: 4.94 ± 0.99, females 4.40 ± 0.94; Student's t-test: t-3.78, p < .001***). No stable correlation between objective vestibular function and subjective sense of spatial orientation was found. A multiple linear regression model could not reliably explain the self-reported variance. The three patient groups with low, average, and high self-assessment-scores showed no significant differences of vestibular function.
CONCLUSION: Self-reported assessment of spatial orientation does not robustly correlate with objective peripheral vestibular function. Therefore, other methods of measuring spatial skills in real-world and virtual environments are required to disclose orientation deficits due to vestibular hypofunction.
Sarilumab 200 mg SC injection q2w for 16 weeks during principal treatment period (Part A) with background therapy of Prednisone (or equivalent oral corticosteroid) ≥15 mg/day and \<80 mg/day as single therapy or in combination with MTX 10 to 25 mg/week and folic acid per local prescribing practice. Responders continued with the same treatment regimen up to Week 50 during extension treatment period (Part B) and non-responders were proposed to be treated with open-label Sarilumab 200 mg q2w in open-label treatment period (Part-C).
Chronic ankle instability is very common in adolescent female basketball players. In the literature neuromuscular exercise programs are often used for prevention in sport players that usually contains of strength and/or balance exercises. Perturbation exercises are oftenly used in sport players for returning the sport or prevention but literature lacks of its effects statistically. This study will investigate if it is possible to achieve improvements on peroneal eccentric strength, fatigue, dynamic balance and individual's performance with the exercises mainly based on side perturbations. Strength and fatigue evaluations will be made with Cybex dynanometer. Dynamic balance evaluations will be made with Y-Balance Tests. Individual's performance parameter evaluations will be made with vertical jump test, cross jump test and side hop test.
Patients randomized to vernakalant will receive a 10-minute infusion of 3 mg/kg vernakalant, followed by a 15 minute observation period. If the patient is still in atrial fibrillation, an additional 10-minute infusion of 2 mg/kg vernakalant will be given. If the patient is still in AF 1 hour after the infusion, electrical cardioversion will be performed according to protocol.
Bladder cancer aggressiveness is correlated with abnormal N-cadherin transmembrane glycoprotein expression. This protein is cleaved by the metalloprotease ADAM10 and the γ-secretase complex releasing a pro-angiogenic N-terminal fragment (NTF) and a proliferation-activating soluble C-terminal fragment (CTF2). Tetraspanin 15 (Tspan15) is identified as an ADAM10-interacting protein to induce selective N-cadherin cleavage. We first demonstrated, in invasive T24 bladder cancer cells, that N-cadherin was cleaved by ADAM10 generating NTF in the extracellular environment and leaving a membrane-anchored CTF1 fragment and that Tspan15 is required for ADAM10 to induce the selective N-cadherin cleavage. Targeting N-cadherin function in cancer is relevant to preventing tumor progression and metastases. For antitumor molecules to inhibit N-cadherin function, they should be complete and not cleaved. We first showed that the GW501516, an agonist of the nuclear receptor PPARβ/δ, decreased Tspan15 and prevented N-cadherin cleavage thus decreasing NTF. Interestingly, the drug did not modify ADAM10 expression, which was important because it could limit side effects since ADAM10 cleaves numerous substrates. By targeting Tspan15 to block ADAM10 activity on N-cadherin, GW501516 could prevent NTF pro-tumoral effects and be a promising molecule to treat bladder cancer. More interestingly, it could optimize the effects of the N-cadherin antagonists those such as ADH-1 that target the N-cadherin ectodomain.
An antibiotic and deodorant material and a preparation method thereof are provided. At first, a mesoporous molecular sieve, a grafting agent and a solvent are reacted under a thermal flux system. The grafting agent has a structure of chemical formula I or II, wherein R 1  and R 2  are alkyl groups having 1 to 20 carbon atoms. The grafting agent can modify surfaces of the mesoporous molecular sieve. Then, the surfaces of the mesoporous molecular sieve are modified by silver ions. Finally, the mesoporous molecular sieve is reduced by a reducing agent to form an antibiotic and deodorant material.
The 3 major forms of leishmaniasis are visceral, cutaneous, and mucosal disease. Of these, mucosal leishmaniasis (ML) arguably poses the most difficult therapeutic problem. Although visceral disease (VL) occurs in perhaps 300,000 persons a year \[Alvar 2012\] and is rapidly fatal since TH1 immunity is lacking, visceral disease is well-treated by drugs. Whereras cutaneous disease (CL) is the most prevalent major form occurring in perhaps 1,000,000 persons a year \[Alvar 2012\], TH1 Immunity is present and CL self-resolves in 3-18 months. CL is treated to speed healing of the cutaneous lesion and, for certain species, to try to prevent dissemination of parasites to the oro-nasal mucosa resulting in mucosal leishmaniasis .

Mucosal leishmaniasis (ML) is estimated to occur as a late sequella in approximately 3% of L braziliensis CL \[Cincura 2017\]. If there are approximately 130,000 cases per year of L braziliensis cutaneous disease \[Alvar 2012\], and 3% of these are succeeded by ML, the approximately 4,000 yearly cases of L braziliensis ML makes ML far less common than VL or CL. However, and in spite of more TH1 immunity than cutaneous disease \[Carvalho 1985\], self-cure of ML is so rare as to be reportable \[Marsden 1991\]. The patient with ML experiences inexorable erosion of the cartilage of the nose, pharynx, palate, and larynx. ML has been difficult to treat with classical agents (a cure rate of approximately 71%: see section 1.2). Thus, of the 3 common forms of leishmaniasis, ML is the form that combines disease severity with poor response to chemotherapy.
System and method for assessing preterm delivery risk for pregnant subject is disclosed. Existing preterm delivery risk assessment methods provide results in late second or third trimester of pregnancy, so little time is available for medical advice. Presently disclosed method and system predict preterm delivery risk within 15 weeks of pregnancy. Microbiome characterization data obtained from microbiome sample from pregnant subject. ‘Microbial taxonomic abundance profile’ generated from microbiome characterization data, contains abundance values of microbes present in the microbiome sample. ‘Taxonomic Composition Skew’ value, and distribution characteristic value for ‘microbial taxonomic abundance profile’, quantifying biases in abundance values of microbes from the microbial taxonomic abundance profile, is computed. Risk of preterm delivery is determined based on the distribution characteristic value or ‘taxonomic composition skew’ value of the set DSR, wherein the set DSR comprises values quantifying biases in the abundance values of microbes from the microbiome sample.
INTRODUCTION: There is a lack of evidence that the benefits of screening for atrial fibrillation (AF) outweigh the harms. Following the completion of the Screening for Atrial Fibrillation with ECG to Reduce stroke (SAFER) pilot trial, the aim of the main SAFER trial is to establish whether population screening for AF reduces incidence of stroke risk.
METHODS AND ANALYSIS: Approximately 82 000 people aged 70 years and over and not on oral anticoagulation are being recruited from general practices in England. Patients on the palliative care register or residents in a nursing home are excluded. Eligible people are identified using electronic patient records from general practices and sent an invitation and consent form to participate by post. Consenting participants are randomised at a ratio of 2:1 (control:intervention) with clustering by household. Those randomised to the intervention arm are sent an information leaflet inviting them to participate in screening, which involves use of a handheld single-lead ECG four times a day for 3 weeks. ECG traces identified by an algorithm as possible AF are reviewed by cardiologists. Participants with AF are seen by a general practitioner for consideration of anticoagulation. The primary outcome is stroke. Major secondary outcomes are: death, major bleeding and cardiovascular events. Follow-up will be via electronic health records for an average of 4 years. The primary analysis will be by intention-to-treat using time-to-event modelling. Results from this trial will be combined with follow-up data from the cluster-randomised pilot trial by fixed-effects meta-analysis.
ETHICS AND DISSEMINATION: The London-Central National Health Service Research Ethics Committee (19/LO/1597) provided ethical approval. Dissemination will include public-friendly summaries, reports and engagement with the UK National Screening Committee.
TRIAL REGISTRATION NUMBER: ISRCTN72104369.
Participants are given intravenous administration of Camrelizumab (200mg/3w) in addition with intravenous administration of Albumin Paclitacxel (135mg/m2, d1, d8/3w, 4-6 cycles) and Apatinib (250mg Qd po for 5 days,, take rest for 2 days every week). Treatment terminates when disease progression, death or unacceptable toxicity.
PROBLEM TO BE SOLVED: To provide an antimicrobial and deodorant spray which is free of the settlement and sepn. during preservation and the closure trouble of a spraying nozzle during use and is free of a sticking feel. SOLUTION: This compsn. is prepd. by dissolving an antimicrobial component having a good drying property into a low b.p. alcohol and drying and solidifying the soln. to particles after spray evaporation. In such a case, one or more kind of the group consisting of magnesium undecylenate, magnesium ricinolate, zinc ricinolate and calcium ricinolate and <=3C monohydric alcohol are used as indispensable components. The low b.p. component having a vapor pressure above the atm. pressure at ordinary temp. is the indispensable component thereto.
After having been informed about the study and the potential risks, all subjects giving written informed consent will undergo screening to determine eligibility for study entry (inclusion criteria). At baseline, the participants will provide biological samples and they will be randomly assigned in a double-blind manner (investigator and participant) to one of the intervention groups, i.e. consumption of the novel biscuit (biscuit enriched with mushroom powder containing 3g of β-glucans) or consumption of the placebo biscuit for 3 months,. After a washout period of 2 months, the subjects will consume the novel biscuit or the placebo biscuit in a cross-over design for 3 more months. Throughout the interventional period subjects' dietary intake, anthropometrical data and gastrointestinal symptoms will be monitored. Meanwhile at baseline and at the end of each trimester physical activity, mental health and sleep habits will be evaluated with the use of questionnaires and biological samples will be provided for further analysis.
Patients with oligometastatic HER2+ breast cancer who were treated with trastuzumab-emtansine and who had a history of SRT. Retrospectively, using CT and MRI data, the dynamics of the process will be evaluated according to the RECIST 1.1. Based on the data of the medical documentation of patients, the main statistical indicators will be calculated.
The invention discloses a traditional Chinese medicine powder used for treating cervical erosion. The traditional Chinese medicine powder is prepared from lightyellow sophora root, swordlike atractylodes rhizome, amur corktree bark, panax notoginseng, rhubarb, musk, common cnidium fruit, oyster, longleaf garden burnet root, gordon euryale seed, and the like. The medicine materials are respectively dried, and are crushed and fully mixed, such that the medicine product provided by the invention is obtained. The product is used for treating cervical erosion, and causes no toxicity, no harm, and no pain to the patients. The medicine powder is time-saving and effort-saving. The medicine powder is advantaged in wide medicine sources, low cost, simple preparation method, and substantial treatment effect.
Fostamatinib is a splenic tyrosine kinase (SYK) inhibitor whose indications include the treatment of chronic primary immune thrombocytopenia (PTI) refractory to first-line treatments. Data from two phase 3 studies in PTI, together with supporting safety data from a comprehensive program in 3,437 subjects with rheumatoid arthritis, led to the approval and registration of fostamatinib by health authorities in the US and in Europe.

Given the recent commercialization of fostamatinib for PTI, there is little data in real clinical practice that helps its general management: how to perform tapering, response rates in less refractory patients, experience in subjects with associated immunosuppressive therapies or thrombopoietin analogues, etc. These studies outside the clinical trial environment are relevant to plan needs, consumption, efficacy, and safety results in real clinical practice in our environment, the Andalusian region. The pivotal studies present experience on 102 cases and the real-life experience is of case series of less than 5 patients, with the population of patients treated in the Andalusian region as of December 31st being greater than 40 cases. For all these reasons the Andalusian Group of Congenital Coagulopathies proposes collecting what the experience has been like in their environment. Participation in this study is not intended to change the routine treatment patients receive as determined by their prescribing physicians. No clinic visits, procedures, evaluations, or tests will be required for the purposes of the study. This is multicenter retrospective data that will be collected from information generated during routine examinations and treatments performed by the investigator according to the standard of care.
Maraviroc antagonizes the CCR5 co-receptor located on some immune cells, and therefore could potentially increase the risk of developing infections. The overall incidence and severity of infection, as well as AIDS-defining category C infections, were comparable in the treatment groups during the Phase 3 adult treatment-experienced trials of maraviroc. While there was a higher rate of certain upper respiratory tract infections reported in the treatment arm receiving maraviroc compared with placebo (23% versus 13%), there was a lower rate of pneumonia (2% versus 5%) reported in subjects receiving maraviroc. A higher incidence of Herpes virus infections (11 per 100 patient-years) was also reported in the treatment arm receiving maraviroc when adjusted for exposure compared with placebo (8 per 100 patient-years).   
In the Phase 2b/3 trial in treatment-naive adult subjects, the incidence of AIDS-defining Category C events when adjusted for exposure was 1.8 for maraviroc compared with 2.4 for efavirenz per 100 patient-years of exposure.   
Patients should be monitored closely for evidence of infections while receiving maraviroc.
Overdosage of dexmedetomidine HCl can cause the adverse reactions generally associated with dexmedetomidine HCl administration [see Warnings and Precautions (5) and Adverse Reactions (6)]. However, these reactions may be more severe. Heart block (e.g., first degree atrioventricular block, second degree heart block) has been reported following overdosage with dexmedetomidine HCl. Cardiac arrest has been reported following loading bolus administration of undiluted Dexmedetomidine HCl Injection.

Dexmedetomidine HCl Injection must be diluted prior to administration [see Dosage and Administration (2.1)]. Management of overdosage should include general supportive measures to sustain the patient through any period of toxicity that may occur.